ALMS1 and Insulin resistance: Recent studies [28] have shown that the C-peptide level is an important index of early-onset type 2 diabetes patients, and the frequency of ALMS1 pathogenic mutations in early-onset type 2 diabetes patients with insulin resistance is greater than that in other groups, but the median age of onset was 16 years old.